UPDATE: Needham On Liquidia Price Target Raise: Positive On 'Tentative FDA Approval For The Treatment Of Pulmonary Arterial Hypertension' Given Yutrepia Meets All FDA Standards For Approval; Sees Co. 'In A Much Stronger Position' Ahead Of March 2022 Trial